[PDF][PDF] The changing role of radium-223 in mCRPC: has the European Medicines Agency missed the mark with revising the label?
T Van den Wyngaert, B Tombal - The Quarterly Journal of Nuclear …, 2019 - dial.uclouvain.be
ABSTRACT 1 Radium-223 is a life prolonging treatment in symptomatic men with metastatic
castrate 2 resistant prostate cancer (mCRPC) and bone metastases, but no visceral disease …
castrate 2 resistant prostate cancer (mCRPC) and bone metastases, but no visceral disease …